$NVCT News

Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas

Nuvectis Pharma Reports Data From Its Phase 1b Trial Of NXP200 Demonstrates Objective Response Rate Based On Response Assessment In Neuro-Oncology Criteria 2.0 Of 40%; Deep Responses Were 87.5%

Nuvectis Pharma to Participate in the Maxim Growth Summit 2026

Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target

Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation

Nuvectis Pharma: Haisco Licensing Deal Revitalises Biotech - But No Rush To Invest Today

Nuvectis Pharma To Participate in Upcoming Investor Conferences

Cantor Fitzgerald Initiates Coverage On Nuvectis Pharma with Overweight Rating

Nuvectis Pharma Files Base Prospectus Related To The Offer And Sale Of Up To $200M Of Securities

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights

Nuvectis Pharma Q2 EPS $(0.30) Misses $(0.26) Estimate

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Nuvectis Pharma's Ciprocopan Receives Marketing Approval From National Medicinal Products Administration Of China To Treat Paroxysmal Nocturnal Hemoglobinuria

StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

Roth Capital Maintains Buy on Nuvectis Pharma, Raises Price Target to $33

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?